Tumors comprise genetically heterogeneous cell populations, whose growth and survival depend on multiple signaling pathways. This has spurred the development of multitargeted therapies, including small molecules that can inhibit multiple kinases. A major challenge in designing such molecules is to determine which kinases to inhibit in each cancer to maximize efficacy and therapeutic index. We describe an approach to this problem implementing RNA interference technology. In order to identify Akt-cooperating kinases, we screened a library of kinase-directed small interfering RNAs (siRNAs) for enhanced cancer cell killing in the presence of Akt inhibitor A-443654. siRNAs targeting casein kinase I gamma 3 (CSNK1G3) or the inositol polyphosphate multikinase (IPMK) significantly enhanced A-443654-mediated cell killing, and caused decreases in Akt Ser-473 and ribosomal protein S6 phosphorylation. Small molecules targeting CSNK1G3 and/or IPMK in addition to Akt may thus exhibit increased efficacy and have the potential for improved therapeutic index.
Introduction
Aberrantly active protein kinases have been implicated in a variety of cancers and represent an important class of drug targets (Blume-Jensen and Hunter, 2001; Cohen, 2002; Dancey and Sausville, 2003; Melnikova and Golden, 2004) . Currently marketed biologics and small molecules targeting kinases are proving effective against well-characterized cancers. For example, the monoclonal antibody trastuzumab (Herceptin), which binds and inhibits the receptor tyrosine kinase HER2, is effective in treating metastatic breast tumors overexpressing HER2, and the small molecule inhibitor imatinib (Gleevec), which targets the ABL tyrosine kinase, is highly effective in treating chronic myelogenous leukemias arising from BCR-ABL translocations (Druker, 2002; Shawver et al., 2002) . Unfortunately, most tumors are more heterogeneous and poorly characterized, making it difficult to treat them effectively with a single agent. Combination therapies targeting multiple signaling pathways may prove more effective, but the clinical trials involved are necessarily more complex and expensive. An alternative is to focus on the production of rationally designed multitargeted kinase inhibitors. This approach assumes, first, that one can identify the kinases that are crucial to inhibit in a particular cancer, and that one can then synthesize a single molecule capable of inhibiting each of these targets. The majority of small molecule kinase inhibitors competitively inhibit ATP binding, and because the ATP-binding pockets of most kinases are structurally similar, this family may be especially amenable to the design of multitargeted inhibitors. Armed with an increasing body of kinase structural and functional data, it may eventually be possible to customdesign small molecules with highly specific selectivity profiles.
A potentially important cancer target is the oncogenic serine-threonine kinase Akt (also referred to as protein kinase B, PKB). Akt functions downstream of the phosphatidylinositol 3-kinase (PI3K) and PI3K-dependent kinases 1 and 2 (PDK1 and PDK2) (see Hanada et al., 2004 for a review). The tumor suppressor PTEN (phosphatase and tensin homolog) antagonizes PI3K signaling, and normally keeps Akt activity in check. Loss of PTEN function leads to aberrantly activated Akt, which has been implicated in the growth and survival of numerous cancers (Vivanco and Sawyers, 2002; Luo et al., 2003; Hanada et al., 2004; Mitsiades et al., 2004; Vara et al., 2004) . We recently reported the discovery of potent and selective Akt inhibitors that slow tumor growth in animal models (Luo et al., 2005) . It may be possible to improve the efficacy and therapeutic index of these inhibitors by simultaneously inhibiting other kinases that cooperate with Akt to maintain cancer cell growth and survival. To explore this idea, we designed an RNA interference (RNAi)-based screen that takes advantage of our most potent and selective Akt inhibitor, A-443654. Using the PTEN-deficient renal carcinoma cell line 786-O, we screened for kinase-directed small interfering RNA (siRNAs) that, in combination with a low dose of A-443654, induce potent cell killing. Using this approach we identified multiple kinases that may be useful to inhibit in combination with Akt. In addition, we were able to identify potential modulators of Akt signaling.
Results
Design of the screen Our immediate aim was to identify siRNAs that induce potent cell killing in combination with partially inhibited Akt. For our studies we used the indazole pyridine-based compound A-443654 (Figure 1a) , an ATP-competitive inhibitor that selectively and potently inhibits all three Akt family members (Luo et al., 2005) . We hoped to sensitize Akt-dependent cancer cells to siRNAs targeting Akt-cooperating kinases. To accomplish this we first determined concentrations of A-443654 that could partially inhibit Akt with minimal cellular toxicity. The PTEN-deficient renal carcinoma cell line 786-O exhibits constitutive Akt activity, and when treated with A-443654 exhibits a dose-dependent decrease in the phosphorylation of Akt substrates (Figure 1b) . While Akt inhibition could be observed at concentrations as low as 0.1-0.3 mM A-443654, significant cytotoxicity only occurred at 0.8-1.6 mM ( Figure 1c ). We thus chose to perform our screen in the presence of 0.5 mM A-443654, in essence rendering Akt hypo-functional and leaving a suitable window for additional, siRNA-induced cellular toxicity.
Identification of potential Akt-cooperating kinases
The long-term aim of our study was to boost the efficacy of Akt inhibitors by extending their effects to key, Aktcooperating kinases. We therefore employed a library of synthetic siRNAs covering the human kinome (see Materials and methods). 786-O cells were transfected with each siRNA in triplicate, using a 96-well format. The next day cells were treated with 0.5 mM A-443654, and after an additional 48 h cell supernatants were isolated to assess cell death. Figure 2a depicts representative results obtained with one portion of the library, which included 55 unique siRNAs (the complete data set is available as supplementary material). Significant hits were judged as those giving cell killing at or above one standard deviation from the population mean. For example, the siRNA against casein kinase 1 g3 (CSNK1G3) caused a significant increase in cell death relative to the rest of the population ( Figure 2a) .
As certain siRNAs are likely to cause cell killing on their own, 105 potential hits were selected and retested in the presence or absence of 0.5 mM A-443654 to identify those that are dependent upon Akt inhibition.
As expected, some of the siRNAs induced cell killing in the presence or absence of drug (Figure 2b ). However, some caused significant cell killing only in the presence of A-443654 (Figure 2b ), including those targeting CSNK1G3, inositol polyphosphate multikinase (IPMK), mitogen-activated protein kinase-activated protein kinase-2 (MAPKAPK-2 or MK2), p90 ribosomal S6 kinase B (RSKB), mitogen-activated protein kinase kinase kinase kinase 2 (M4K2), and membrane protein palmitoylated 1 (MPP1). We were thus able to identify siRNAs that, on their own, had no significant effect on cancer cell viability, but in combination with a low dose of A-443654 caused significant cell killing.
We next analysed several of the drug-specific hits in siRNA dose-response experiments (Figure 3a and data RNAi-based approach to designing multitargeted kinase inhibitors S Morgan-Lappe et al not shown), and confirmed that the CSNK1G3 and IPMK siRNAs caused significant, dose-dependent cytotoxicity in the presence, but not in the absence, of A-443654. Both siRNAs had similar, A-443654-specific effects in the pancreatic carcinoma cell line MiaPaCa-2 (data not shown). We also tested these siRNAs in an additional cellular format, using a standard alamarBlue assay (Materials and methods) to assess their effects on cell growth. As a positive control we implemented an siRNA targeting Polo-like kinase 1 (PLK1), an essential regulator of mitosis. The PLK1 siRNA inhibited cell growth in the presence or absence of A-443654, relative to a PLK1-scrambled siRNA control (Figure 3b ). In the presence of 0.1 and 0.5 mM A-443654, the PLK1 siRNA demonstrated an additive inhibitory effect on cell growth. In the absence of A-443654, CSNK1G3 and IPMK siRNAs also inhibited cell growth as measured by this assay. However, in the presence of 0.5 mM A-443654, the concentration used in the original screen, the CSNK1G3 and IPMK siRNAs inhibited cell growth to a significantly greater extent than PLK1 siRNA (Figure 3b ), indicating a synergy between these siRNAs and A-443654. As an additional control, we tested these siRNAs in the presence of the A-443654 enantiomer (A-443654E), which is approximately 400-fold less potent against Akt in vitro (data not shown). Neither the CSNK1G3 nor the IPMK siRNA enhanced growth inhibition in the presence of 0.5 mM A-443654E, indicating that their effects are likely dependent on Akt inhibition. As siRNAs have the potential for off-target effects (Jackson et al., 2003; Jackson and Linsley, 2004; Scacheri et al., 2004) , we tested several additional siRNAs against CSNK1G3 and IPMK, each targeting a distinct region of the appropriate mRNA. Multiple siRNAs against CSNK1G3 and IPMK proved effective in knocking down the appropriate target message, and caused a drug-dependent decrease in cell viability (Figure 3c ). The ability of the IPMK siRNAs to synergize with A-443654 correlated well with their ability to knockdown the target message, as assessed by real-time quantitative PCR (Figure 3c ). Taken together, these data indicate that the specific knockdown of CSNK1G3 or IPMK confers enhanced cellular toxicity to the Akt inhibitor A-443654.
CSNK1G3 and IPMK as potential Akt-cooperating kinases
We next investigated possible mechanisms for the toxicity that we observed with CSNK1G3 and IPMK siRNAs in the presence of A-443654, hypothesizing that Recent work by others has demonstrated that Akt's effects on mRNA translation are likely central to its transforming/antiapoptotic activity (Wendel et al., 2004) , and so one might expect to identify siRNAs affecting ribosomal protein S6 phosphorylation in screens such as ours. We thus tested the effect of the CSNK1G3 and IPMK siRNAs on S6 ribosomal protein phosphorylation, a p70S6K-mediated event that lies downstream of Akt signaling. In the absence of A-443654, CSNK1G3 and IPMK siRNAs caused a significant decrease in S6 phosphorylation, both at serines 235/236 and 240/244, without affecting S6 levels ( Figure 4c and data not shown). In the presence of 0.3 mM A-443654, S6 phosphorylation is significantly reduced (Figures 1b and 4c) . After CSNK1G3 or IPMK siRNA treatment, this concentration of A-443654 almost completely abolished S6 phosphorylation. S6 phosphorylation was unaffected by either PLK1-SCR or MAPKAPK-2 siRNAs, indicating that this effect is specific for CSNK1G3 or IPMK knockdown. These results indicate that CSNK1G3 and/or IPMK may contribute to the activation of p70S6K1, either via Akt or through other mechanisms (see Discussion).
In conclusion, our study demonstrates that RNAibased screening can be used in conjunction with small molecule inhibitors to successfully identify kinases that cooperate in cancer cell survival, making it a very useful tool in defining the desired selectivity profiles of multitargeted therapies. In addition, such screens may be useful in further elucidating signaling pathways, and our preliminary data indicate that CSNK1G3 and IPMK may contribute to the regulation of Akt signaling.
Discussion
As the complex signaling pathways governing cancer cell growth and survival are elucidated, the rational design of multitargeted inhibitors may become feasible. One challenge will be to determine which targets to inhibit in each type of cancer. As demonstrated here, RNAi technology provides a powerful approach to this problem. We implemented an RNAi-based screen to identify kinases that cooperate with Akt in maintaining cancer cell survival. siRNAs targeting CSNK1G3 or IPMK enhanced cancer cell killing in the presence of Akt inhibitor A-443654. In addition, we found evidence that both kinases may contribute to the regulation of Akt or events downstream of Akt. Our work thus demonstrates how RNAi-based screening can be used to optimize an inhibitor's selectivity profile, and also its power as a genetic tool in elucidating biological signaling pathways.
Other RNAi-based screens in mammalian cells have recently been described. For example, Aza-Blanc et al. RNAi-based approach to designing multitargeted kinase inhibitors S Morgan-Lappe et al future combination regimens. Our screen was designed with the long-term aim of improving the efficacy of a kinase-directed small molecule inhibitor. By starting with a potent and selective compound, we were able to interrogate a specific pathway in a specific genetic background, that is, the Akt cell survival pathway in a PTEN-deficient cancer cell line. Employing our inhibitor allowed us to precisely control the level of Akt activity, rendering it hypo-functional, and thereby sensitizing cells to siRNAs affecting Akt-mediated cell survival. Our approach thus resembles classical synthetic-lethal screens (Forsburg, 2003) , which begin with a defined hypo-functional allele and implement random mutagenesis to identify genes of interest. While such powerful genetic approaches have historically been limited to model organisms such as yeast, RNAi technology makes mammalian systems genetically tractable, and allows one to screen through a defined subset of targets. We focused on kinases because of their inherent druggability, with the aim of developing efficacious multitargeted inhibitors.
Potential mechanisms for siRNA-induced, A-443654-dependent cell killing Several mechanisms can explain the drug-dependent toxicity we observed with our siRNA hits ( Figure 5 ). In the ideal scenario, the siRNA inhibits a kinase that is cooperating with Akt to maintain cell survival. This kinase could act in parallel to or within Akt survival pathways ( Figure 5b , left and center panels). Alternatively, A-443654 could partially inhibit another essential kinase nonselectively at the concentration used. When that kinase is knocked down by siRNA, the inhibitor concentration present may be sufficient to induce cellular toxicity (Figure 5b , right panel). In the case of MAPKAPK-2, this scenario is unlikely, as A-443654 is highly selective for Akt (IC 50 ¼ 200 pM versus Akt1 and 2 mM versus MAPKAPK-2). Although IPMK is an inositol polyphosphate kinase (IPK), it remains possible that A-443654 can inhibit it at the concentration used. IPKs diverge from protein and lipid kinases in their primary sequences, and yet their ATP-binding pockets share some structural similarity (Gonzalez et al., 2004) . This is important to note in another regard, as it implies that it may be possible to synthesize single agents capable of inhibiting both Akt and IPMK. In the case of our two best hits, CSNK1G3 and IPMK, the siRNAs functioned potently with A-443654, but not with the same concentration of its enantiomer, which is significantly less potent against Akt. While this result indicates that Akt inhibition is required for the toxic effects of CSNK1G3 and IPMK siRNAs, the possibility remains that they are instead synergizing with other, nonselectively inhibited targets of the drug. We are currently testing additional, structurally diverse classes of Akt inhibitors to further confirm the link between Akt and CSNK1G3 and/or IPMK. As it is also possible that the siRNAs identified in such screens exert off-target effects, each hit needs to be confirmed using multiple siRNAs targeting distinct regions of the appropriate mRNA. Multiple siRNAs targeting CSNK1G3 or IPMK caused the same, A-443654-dependent cell killing in our assay, indicating that the effects we observed require the specific, siRNAmediated knockdown of those targets.
Our initial data indicate that CSNK1G3 and IPMK may directly participate in Akt signaling. Both kinases seem to play a role in the Akt-activating phosphorylation at Ser-473. Recently, Sarbassov et al. RNAi-based approach to designing multitargeted kinase inhibitors S Morgan-Lappe et al demonstrated that the Rapamycin-insensitive complex comprising the mammalian target of Rapamycin (mTOR) and Rictor mediates Akt Ser-473 phosphorylation. mTOR and Rictor thus represent possible targets for CSNK1G3 and IPMK, and we are currently investigating these possibilities. Very little is currently known about the gamma 3 isoform of casein kinase 1. Three rat gamma isoforms have been described, with only gamma 3 showing expression outside the testis (Zhai et al., 1995) . Rat CSNK1G3 is able to complement defects associated with casein kinase 1 mutants in yeast, including a YCK1 deletion or a YCK2 temperature-sensitive allele. The human gene has been cloned (Kusuda et al., 1998) and is expressed in most tissues tested. Multiple casein kinase 1 isoforms have been implicated in beta-catenin signaling, but it is noteworthy that, in Xenopus, the gamma 3 isoform consistently demonstrated little or no effect (McKay et al., 2001) . CSNK1G3 likely represents the most divergent member of the CK1 family, and may thus play very specialized roles.
The functions of human IPMK are also poorly understood at present. The majority of IPMK reportedly localizes to the nucleus (Nalaskowski et al., 2002) , and IPMK orthologs in yeast have been implicated in transcriptional regulation and mRNA export (York et al., 1999) . IPMK is catalytically versatile, at least in vitro (see Shears, 2004 for a review), and can phosphorylate either Ins(1,3,4,6)P4 or Ins(1,4,5,6)P4, targeting distinct sites in the inositol ring, to yield Ins(1,3,4,5,6)P5 (IP5). IP5 is present at micromolar concentrations in the cytosol, and has been suggested to affect a variety of signaling pathways. One report suggests that IP5 can bind to the Akt pleckstrin homology (PH) domain, and at high levels may sequester the kinase in the cytosol (Piccolo et al., 2004) . Others have shown that IP5 exhibits higher affinity for the PH domain of PDK1, and that this interaction is more likely to be affected by fluctuations in cellular IP5 levels (Komander et al., 2004) . These authors suggest that IP5 may serve to anchor PDK1 in the cytosol, where it is required to activate specific substrate kinases such as p70S6K1. This model could provide another explanation for our observation that IPMK siRNA causes a reduction in p70S6K1-mediated S6 phosphorylation (Figure 4c) . Indeed, we have observed modest, IPMK siRNAmediated reductions in the phosphorylation of p70S6K1 Thr-229, the site targeted by PDK1 (data not shown).
Recent studies in mammalian cells have confirmed the role of IPMK in producing IP5, the essential precursor of IP6 (Verbsky et al., 2005) . In both rat and human cells, siRNA-mediated knockdown of IPMK leads to dramatically reduced IP5 and IP6 levels. IP6 activates the DNA-dependent protein kinase (DNA-PK) by binding its regulatory subunits Ku70/80 (Hanakahi et al., 2000; Hanakahi and West, 2002; Ma and Lieber, 2002) , and DNA-PK was recently purified as a membrane-bound, Akt Ser-473-phosphorylating activity . In our hands, IPMK siRNA reproducibly caused a decrease in Akt Ser-473 phosphorylation, which may partially account for its effect on A-443654-mediated toxicity. PTEN was recently shown to act as an Ins(1,3,4,5,6)P5 3-phosphatase (Caffrey et al., 2001) . As the cell line used in our studies is PTEN-deficient, the effects of IPMK siRNA on Akt phosphorylation may have been blunted by the absence of this IP5-dephosphorylating activity. Another intriguing possibility is that IPMK can phosphorylate phosphatidyl inositols and activate Akt by increasing PtIns(3,4,5)P3 levels.
siRNA screening and the design of cancer therapeutics The lack of selectivity can complicate the development of small molecule inhibitors as cancer therapeutics. In some cases, the doses required to sufficiently inhibit the primary target cause off-target effects and toxicities. Consequently, the most common approach has been to search for increasingly potent and selective inhibitors. However, it is becoming increasingly clear that the heterogeneous and adaptable nature of most cancers makes them extremely difficult to treat with single agents. This fact has spurred a paradigm shift toward the development of multitargeted inhibitors, which can attack tumors through multiple mechanisms (Bergers et al., 2003; Daub et al., 2004; Pietras and Hanahan, 2005) . Such a 'poly-pharmacy' approach may lead to significant improvements in efficacy, safety, and ultimately the degree of cure achievable. For example, targeting mulitple kinases in tumors may represent an effective means of avoiding the development of drug resistance (Daub et al., 2004) , and of counteracting the plasticity of cancer cell signaling networks and their ability to remodel in response to stresses. In CMLs driven by BCR-ABL, certain point mutations in the Abl kinase domain confer resistance to Gleevec, and have necessitated the development of additional ABL inhibitors (see Deininger and Druker, 2004 for a review). Other CMLs have been suggested to acquire Gleevec resistance by upregulating compensatory signaling molecules, such as the Abl-related Lyn kinase (Donato et al., 2003; Dai et al., 2004) . Small molecule/siRNA combination screens such ours may be useful in identifying such compensatory regulators of survival in these and other cancers. Once identified, these targets can be weighed appropriately in defining a compound's desired selectivity profile. Clearly, applications of RNAi technology such as ours have the potential to facilitate the drug discovery process, and to contribute at many levels to the development of greatly improved therapeutics for the treatment of cancer.
Materials and methods
siRNAs and siRNA library design Our siRNA library targets a total of 507 genes that include 443 known kinases and 64 unique kinase genes of unknown function. All siRNAs were obtained from Dharmacon Research, Inc. (Lafayette, CO, USA) as synthetic doublestranded RNA oligonucleotides. For each target, a single siRNA duplex was synthesized, directed to a unique site in the respective RNA message. The design of our library was based on the rules suggested by Elbashir et al. (2002) , in which the antisense strand of each siRNA was targeted against an AA(N) 19 sequence that was approximately 100 nt downstream of the start codon, and contained a GC content within the range of 40-70%. In addition to following these rules, we used an algorithm based on a computer program that excludes from further consideration regions of the target mRNA that contain extensive stem-loop structures, and regions that are highly homologous to other sequences contained in RefSeq (Semizarov et al., 2003) . On the basis of our previous results, we expect approximately 2/3 of these siRNAs to be functional in target knockdown (50% protein reduction or more 
Cell lines
Human renal carcinoma cell line 786-O was obtained from American Type Culture Collection (ATCC; Manassas, VA, USA) and maintained in RPMI-1640 with 10% fetal bovine serum (GIBCO BRL, Gaithersburg, MD, USA) in a humidified chamber (5% CO 2 ). The pancreatic carcinoma cell line MiaPaCa-2 was also obtained from ATCC and maintained in Dulbecco's modified medium plus 10% fetal bovine serum.
Akt substrate studies 786-O cells were seeded at a density of 1.5 Â 10 6 /10 cm dish. The next day cells were treated with 0-10 mM of the indicated inhibitors (adjusted to contain equal final volumes of DMSO vehicle). Lysates were prepared by sonicating the cells for 5 min in ice-cold insect cell lysis buffer (BD Biosciences Pharmingen, San Diego, CA, USA) supplemented with 1 mM microcystin LR (Sigma, St Louis, MO, USA). Lysate protein concentrations were determined using a standard Bradford assay (Bio-Rad, Hercules, CA, USA). In total, 40 mg of cell lysate were loaded per well for SDS-PAGE. Proteins were transferred onto PVDF membranes and detected using Akt substrate phospho-specific antibodies.
Immunoblotting and antibodies SDS-PAGE was performed using 6 or 10% Tris-glycine mini-gels (Invitrogen, Carlsbad, CA, USA), which were then immunoblotted to PVDF membranes. Phospho-GSK3 a/b Serine 21/9, phospho-TSC2 Threonine 1462, phospho-FOXO1A/3A Threonine 24/32, Akt, phospho-Akt Serine 473, phospho-Akt Threonine 308, phospho-p70S6K1 Threonine 389, phospho-ribosomal protein S6 Serine 235/236 and phospho-ribosomal protein S6 Serine 240/244 rabbit polyclonal antibodies were purchased from Cell Signaling Technology (Beverley, MA, USA). GSK3 a/b mouse monoclonal antibody sc-7291 was purchased from Santa Cruz (Santa Cruz, CA, USA). All primary antibodies were diluted 1:1000 in a 5% milk/TBS-T (w/v) solution. Secondary anti-rabbit-HRP and anti-mouse-HRP antibodies were purchased from Amersham Biosciences (Piscataway, NJ, USA) and used at a dilution of 1:3000. Blots were developed using enhanced chemiluminescence (ECL Plus) reagents from Amersham Biosciences.
siRNA kinome library screen Transfections were performed in 96-well plates using Trans-IT-TKO reagent (Mirus, Madison, WI, USA) and cells that were approximately 60% confluent. For a single well, 0.375 ml of 20 mM siRNA solution and 0.7 ml TransIT-TKO reagent were incubated in 50 ml of Opti-MEM (Invitrogen, Carlsbad, CA, USA) for 20 min at room temperature before being applied to the cells containing 100 ml of medium. The cells were incubated in the transfection mixture at 371C for 4 h before replacement with 150 ml fresh medium. After 24 h, each well received 50 ml of a 2 mM A-443654 stock (0.5 mM final). After 2 days, cell death was assessed using the Toxilight bioluminescent assay (Cambrex, Rockland, ME, USA), according to the manufacturer's instructions. Raw data values were recorded as luciferase units on a 1420 VICTOR Multilabel Counter (PerkinElmer Life Sciences, Downers Grove, IL, USA). Each siRNA transfection was performed in triplicate, spanning three independent 96-well plates. A Z-factor was calculated to determine the overall assay quality, reproducibility, and suitability for HTS (Zhang et al., 1999) . For alamarBlue assays, cells in 96-well plates were gently washed with 200 ml of PBS. AlamarBlue reagent (Biosource International, Camarillo, CA, USA) was diluted 1:10 in 786-O culture medium. Diluted reagent (100 ml) was added to each well and incubated until the reaction was complete as per the manufacturer's instructions. Analysis was performed using an fmax Fluorescence Microplate Reader (Molecular Devices, Sunnyvale, CA, USA), set at the excitation wavelength of 544 nm and emission wavelength of 595 nm. Data were analysed using SOFTmax PRO software provided by the manufacturer.
RNA isolation and Taqman real-time quantitative RT-PCR RNA was isolated using Trizol (Invitrogen, Carlsbad, CA, USA), chloroform extraction, and Qiagen RNeasy mini kit (Valencia, CA, USA), according to the manufacturers' instructions. All primers were purchased from Integrated DNA Technologies (IDT, Coralville, IA, USA). For the RPL19, ACTB and GAPD genes, TaqMant probes were also purchased from IDT. These probes were 5 0 labeled with the reporter 6-carboxyfluorescein (FAM) and 3 0 labeled with the quencher tetramethylrhodamine (TAMRA).
Primers and probes included 5 0 -AAATTCCATGGCA CCGTC-3 0 (forward), 5 0 -GATGGTGATGGGATTTCCA-3 0 (reverse), and 5 0 -CAAGCTTCCCGTTCTCAGCC-3 0 (probe) for the GAPD gene; 5 0 -CTGGAACGGTGAAGGTGACA-3 0 (forward), 5 0 -CGGCCACATTGTGAACTTTG-3 0 (reverse), and 5 0 -CAGTCGGTTGGAGCGAGCATCCC-3 0 (probe) for the ACTB gene, and 5 0 -GCCTGTGACGGTCCATTCC-3 0 (forward), 5 0 -TGGCTGTACCCTTCCGCTTA-3 0 (reverse), and 5 0 -ATGCCCATGTGCCTGCCCTTCCG-3 0 (probe) for the RPL19 gene. For IPMK and CSNK1G3, probes were selected from the ProbeLibraryt (Mouritzen et al., 2004) purchased from Exiqon (Vedbaek, Denmark). The probes were labeled with fluorescein and a nonfluorescent quencher, and relied on the high-affinity locked nucleic acid LNAt analogue nucleotide chemistry for specificity and high temperature binding. The primer-probe sets included: 5 0 -CGGAA GAAGCTTAACAAAAGAAAC-3 0 (forward), 5 0 -TCTTAA GCAGTACCCATTATGAAAAA-3 0 (reverse), and human probe #58 for IPMK, and 5 0 -CGGCCCTTGTGGTAAATA CA-3 0 (forward), 5 0 -CACAAGTCAAACAAGTCTTCCAA-3 0 (reverse), and human probe #3 for CSNK1G3. For each sample, QPCR was performed in a final volume of 25 ml containing 100 ng of RNA, 0.4 mM each of the forward and reverse primers and 100 nM of the TaqMant probe or 80 nM of the Exiqon probe. Temperature conditions consisted of 501C for 30-min, 951C for 5 min, followed by 40 cycles of 601C for 1 min and 951C for 15 seconds on a Prism 7700 and 7900HT sequence detector (Applied Biosystems, Inc., Foster City, CA, USA). Data were collected during each extension phase of the PCR reaction and analysed with the ABI SDS software package. Threshold cycles were determined for each gene. A parallel standard curve (in duplicate) using 100, 33.3, 11.1 and 3.7 ng of universal human reference RNA (Stratagene, Cedar Creek, TX, USA) was generated for each gene. This standard curve was used to determine the relative concentration of RNA in each sample by comparison using methods described in the ABI Prism User Bulletin Number 2. The kinase gene expression values were normalized to the geometric mean of the three control genes, and the relative expression for each sample was divided by the average relative expression value of the scrambled controls to simplify the display of the data.
